You are here: Industry Insights > Liver cancer

News List

EU approves Ipsen’s Cabometyx in second line liver cancer pharmaphorum
November 21, 2018
The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar.
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Eisai/MSD’s Lenvima approved in Europe for liver cancer pharmatimes
August 27, 2018
Eisai and MSD’s Lenvima has won approval in the US as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough fiercepharma
July 19, 2018
Roche’s Tecentriq is on a much-needed hot streak.
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.
Singapore to boost liver cancer treatment biospectrumasia
May 03, 2018
The programme will use Samsung Medical Centre's robotic Avatar Platform, which allows hundreds of sets of cells to be screened at the same time.
Vitamin A derivative selectively kills liver cancer stem cells europeanpharmaceuticalreview
April 26, 2018
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma…
Singapore's Restalyst develops new method to improve liver cancer diagnosis biospectrumasia
November 10, 2017
Restalyst will launch the use of the algorithm at MEDICA 2017, a global forum for medical technology, on November 13-16 in Germany
Singapore's Restalyst develops new method to improve liver cancer diagnosis prnasia
November 09, 2017
Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%.
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions fiercepharma
November 09, 2017
Bayer is working to position Stivarga as part of a treatment regimen for those who have failed on its first-line liver cancer fighter, Nexavar. But that’s not going to work in England. At least, not yet.

Previous page 1 2 3 4 5 Next page